Mantle cell lymphoma
Drug research and approvals for mantle cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 118 studies of mantle cell lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, FDA has 12 approved and 16 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 118
- Trials authorized in Canada: 13
- FDA orphan approvals: 12
- EU medicines: 2
Recruiting Now
Newest start dates first, of 118 recruiting on ClinicalTrials.gov ↗- Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaNCT07578077 · Phase 1 / Phase 2 · City of Hope Medical Center · starts Dec 21, 2026
- Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or…NCT07892027 · Phase 2 · University of Michigan Rogel Cancer Center · starts Nov 1, 2026
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell…NCT06675123 · Phase 1 · City of Hope Medical Center · starts Sep 29, 2026
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non…NCT07763210 · Phase 2 · Vanderbilt-Ingram Cancer Center · starts Sep 25, 2026
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell…NCT07225439 · Phase 1 · Paolo Caimi, MD · starts Sep 1, 2026
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory…NCT07788118 · Phase 1 / Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 1, 2026
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care…NCT07341191 · Phase 2 · Canadian Cancer Trials Group · starts Aug 24, 2026
- Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell LymphomaNCT07673367 · Phase 2 · Vanderbilt-Ingram Cancer Center · starts Jul 31, 2026
- Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell…NCT07719556 · Phase 2 · The First Affiliated Hospital with Nanjing Medical University · starts Jul 15, 2026
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesNCT07609862 · Phase 1 / Phase 2 · Guangzhou Lupeng Pharmaceutical Company LTD. · starts Jul 14, 2026
Trials Authorized in Canada
The 10 newest of 13; search them all in Canada trials| Dec 22, 2025 | A phase II study of sonrotoclax plus zanubrutinib in patients with relapsed/refractory mantle cell lymphoma planned for standard of care car-t cell therapySONROTOCLAX / ZANUBRUTINIB | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Jul 28, 2023 | A multicentre, phase II, open-label study to evaluate the efficacy of acalabrutinib in combination with venetoclax and rituximab in participants with treatment…ACALABRUTINIB/ VENETOCLAX/ RITUXIMAB | AstraZeneca Pharmaceuticals LP | Ongoing |
| Jul 6, 2023 | A phase III, open-label, multicenter, randomized study evaluating glofitamab as a single agent versus investigator¿s choice in patients with…COLUMVI / GAZYVA / RITUXAN / BENDAMUSTINE / LENALIDOMIDE | Roche | Ongoing |
| May 31, 2023 | A phase 1, open-label, multicenter, dose escalation study of prt1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / VENETOCLAX / AZACITIDINE | PRELUDE THERAPEUTICS | Closed |
| Dec 15, 2022 | A single-arm, open-label, multicenter phase 1/2 study to evaluate the efficacy, safety, and pharmacokinetics of bcl-2 inhibitor bgb-11417 in patients with…SONROTOCLAX (BGB-11417) | BeOne Medicines | Closed |
| Oct 26, 2021 | A phase 3 randomized, open-label, multicenter study comparing zanubrutinib (bgb-3111) plus rituximab versus bendamustine plus rituximab in patients with…ZANUBRUTINIB (BGB-3111) / RITUXIMAB/ BENDAMUSTINE | BeOne Medicines | Ongoing |
| Mar 19, 2021 | A phase 3 open-label, randomized study of loxo-305 versus investigator choice of btk inhibitor in patients with previously treated btk inhibitor naïve mantle…PIRTOBRUTINIB (LOXO-305) | Eli Lilly | Ongoing |
| Jul 24, 2020 | A phase II study of acalabrutinib in combination with r-chop chemotherapy in previously untreated mantle cell lymphomaACALABRUTINIB | UNIVERSITY HEALTH NETWORK | Ongoing |
| May 2, 2018 | A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of amg 562 in subjects with relapsed /…AMG 562 | Amgen | Closed |
| Jun 22, 2017 | Phase 3 study of ibrutinib in combination with venetoclax in subjects with mantle cell lymphomaIBRUTINIB/ VENETOCLAX/ FLUDEOXYGLUCOSE 18F | AbbVie | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 28| May 13, 2026 | Beqalzitreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including… | BeOne Medicines USA, Inc. | Approved |
| Jan 16, 2025 | Calquencein combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who… | Acerta Pharma, LLC (a member of the AstraZeneca Group) | Approved |
| May 30, 2024 | Breyanzitreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic… | Juno Therapeutics, Inc. | Approved |
| Jan 27, 2023 | Jaypircatreatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including… | Loxo Oncology, Inc. | Approved |
| Aug 4, 2022 | CalquenceTreatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy | Acerta Pharma, LLC (a member of the AstraZeneca Group) | Approved |
| Jul 24, 2020 | TECARTUS™TECARTUS¿ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) | Kite Pharma, Inc. | Approved |
| Nov 14, 2019 | BRUKINSABRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. | BeOne Medicines USA, Inc. | Approved |
| Oct 31, 2017 | CALQUENCEtreatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy | Acerta Pharma, LLC (a member of the AstraZeneca Group) | Approved |
| Oct 8, 2014 | VelcadeTreatment of patients with mantle cell lymphoma. | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Nov 13, 2013 | ImbruvicaTreatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy | Pharmacyclics, LLC | Approved |
| Jun 5, 2013 | RevlimidTreatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. | Celgene Corporation | Approved |
| Dec 8, 2006 | VelcadeTreatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Feb 25, 2025 | an antibody-drug conjugate composed of the humanized…treatment of mantle cell lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd | Designated |
| Feb 20, 2024 | CAR-T cell engager protein that links the CD19-directed…Treatment of mantle cell lymphoma | Aleta Biotherapeutics | Designated |
| Dec 5, 2023 | tacabrutidegTreatment of Mantle Cell Lymphoma | BeOne Medicines USA, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Oct 30, 2023 | Jaypircapirtobrutinib | Eli Lilly Nederland B.V. | EMA ↗ |
| Dec 14, 2020 | Tecartusbrexucabtagene autoleucel · orphan | Kite Pharma EU B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA